Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT06789432

Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population

Led by Dr. Md. Alimur Reza · Updated on 2025-07-29

500

Participants Needed

1

Research Sites

43 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to evaluate the efficacy and safety of a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy in the Bangladeshi population. Researchers will compare atorvastatin (10 mg) and ezetimibe (10 mg) to atorvastatin (20 mg) monotherapy to see if atorvastatin (10 mg) and ezetimibe (10 mg) FDC works to treat dyslipidemia. Participants will: * Take a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy for 3 months * Follow-up visits at 6 weeks and 12 weeks for checkups and tests

CONDITIONS

Official Title

Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men and women aged over 18 years
  • Confirmed diagnosis of elevated LDL-C levels requiring medical management
  • Low to moderate cardiovascular disease risk according to ESC guidelines (2019)
    • Low-risk: Increased LDL-C without other co-morbidities
    • Moderate-risk: Young patients with type 1 diabetes under 35 years or type 2 diabetes under 50 years with diabetes duration less than 10 years and no other risk factors
Not Eligible

You will not qualify if you...

  • History of hypersensitivity to any study drugs
  • Significant liver impairment (ALT, AST levels more than twice upper limit of normal)
  • Significant kidney impairment (serum creatinine levels at least twice upper limit of normal)
  • Presence of hepatitis B or C with cirrhosis, end-stage liver disease, cancer, psychiatric instability, HIV positive status, or intestinal malabsorption
  • Pregnant or breastfeeding females
  • Any condition that investigator believes increases risk from study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Popular Medical College & Hospital

Dhaka, Dhaka Division, Bangladesh

Actively Recruiting

Loading map...

Research Team

D

Dr. Md. Alimur Reza, MBBS, MPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population | DecenTrialz